Walgreens Boots Alliance price target raised to $10 from $9 at UBS

UBS raised the firm’s price target on Walgreens Boots Alliance to $10 from $9 and keeps a Neutral rating on the shares after hosting meetings with the company’s management team. CEO Tim Wentworth said Tuesday was “the best day he’s had as CEO” since taking over the role in late 2023, attributing his mood to the positive stock reaction and relatively upbeat results, the analyst tells investors in a research note. Commentary on FY25 and an implied read-through to FY26 suggest a recovery in adjusted EPS and reported free cash flow are still at least a year or two away, the firm says, adding that a sale of VillageMD and/or Summit/CityMD are the primary catalysts that could meaningfully speed up the pace of an EPS/FCF turnaround.